Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "obesity-medicines"

4 News Found

Lilly expands affordable access to diabetes & obesity medicines under new medicare programme
Supply Chain | March 10, 2026

Lilly expands affordable access to diabetes & obesity medicines under new medicare programme

Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans

Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors
News | May 25, 2026

Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors

The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks

FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment
Drug Approval | February 24, 2026

FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment

In 2025, over 1 million patients accessed Lilly treatments through LillyDirect

Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook
News | February 05, 2026

Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook

US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices

Upcoming E-conference
June 19, 2026 The Future of Clinical Research in India: Can India Become a Global Trial Hub?

Latest Stories

Merck’s KEYTRUDA combo wins key EU backing for bladder cancer treatment

Datroway wins US nod in aggressive breast cancer subtype

Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare
Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare
Dr Vidya Veldore Vice President, Clinical Operations, 4baseCare
AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
Dushyant Sapre Founder and CEO, SwishX
Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital
Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital
Duraisamy Rajan Palani Founder and CEO, Archimedis Digital

Packaging